Share on StockTwits

Stemline Therapeutics (NASDAQ:STML) Director Kenneth J. Zuerblis purchased 1,000 shares of the company’s stock on the open market in a transaction dated Tuesday, September 2nd. The shares were purchased at an average cost of $11.14 per share, with a total value of $11,140.00. Following the acquisition, the director now directly owns 11,963 shares of the company’s stock, valued at approximately $133,268. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Stemline Therapeutics (NASDAQ:STML) traded down 0.64% during mid-day trading on Thursday, hitting $10.85. The stock had a trading volume of 67,538 shares. Stemline Therapeutics has a 1-year low of $10.509 and a 1-year high of $47.25. The stock has a 50-day moving average of $11.61 and a 200-day moving average of $16.36. The company’s market cap is $140.5 million.

Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.71) by $0.24. On average, analysts predict that Stemline Therapeutics will post $-2.39 earnings per share for the current fiscal year.

Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.